

# Technology Development Group

# Available Technologies

# Contact Our Team

**Request Information** 

**Permalink** 

## **Novel Mouse Model for Huntingtons Disease**

Tech ID: 20506 / UC Case 2005-492-0

#### **BACKGROUND**

Huntingtons disease (HD) is a neurodegenerative disease characterized by the adult-onset of abnormal movement, psychiatric disturbances, and cognitive impairment. The disease usually progresses relentlessly and results in the patients death within 15-20 years of its onset. Currently, there is no effective treatment for HD.HD is caused by a mutation in the first exon of the huntingtin gene (htt), which encodes a 350kD, ubiquitously expressed protein of unknown function. Mutant htt (mhtt) is thought to acquire dominant toxicities through the expansion of polyglutamine repeats. However, the precise mechanism by which various forms of mhtt cause HD is not clear. Transgenic mice have been a very useful genetic tool to study gene regulation and the effect of gene overexpression in vivo. Although several mouse models of HD have been generated to study HD, they either lack robust and selective neurodegeneration or have a relatively slow and mild disease process. Therefore, the need exists for transgenic mice that exhibit robust motor deficits and neuropathology phenotypes which make them more suitable to examine HD pathogenesis and to test candidate therapeutics.

### **INNOVATION**

UCLA researchers have generated novel mouse models of HD using Bacterial Artificial Chromosome (BAC) transgenic technology. Western blot analyses demonstrate that the transgenic mice broadly express full length mhtt in the brain at approximately the same level as the endogenous murine wildtype htt. These mice exhibit progressive and robust motor deficits demonstrated by Rotarod and open field tests. These mice accumulate mhtt aggregates and inclusions in a brain and subcellular distribution pattern similar to that of HD patients. Neuropathological studies demonstrated that these mice exhibit highly selective brain atrophy and neurodegeneration in the cortex and striatum, but not in other brain regions spared in HD. Therefore, these mice represent a robust full length mouse model suitable to study HD pathogenesis and to test therapeutic compounds and strategies for HD.

#### **APPLICATIONS**

- Transgenic HD mice can be used to study the pathogenesis of HD.
- Transgenic HD mice can be utilized to test therapeutic compounds and strategies for HD.

#### **ADVANTAGES**

- ▶ BAC transgenic system can consistently produce high levels of and endogenous-like transgene expression in vivo.
- Transgenic HD mice exhibit progressive and robust motor deficiencies as compared to other mouse models.
- Transgenic HD mice display neuropathology which is strikingly similar to HD patients.

### PATENT STATUS

Patent Pending

### ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

- Transgenic Mouse Model of Parkinson's Disease with Age-Dependent Hypokinetic Motor Deficits, Dopaminergic Neuron Loss, and Alpha Synuclein Accumulation
- ▶ Rosa HD
- ▶ A Cell-Based Seeding Assay for Huntingtin Aggregation

#### CONTACT

UCLA Technology Development Group

ncd@tdg.ucla.edu tel: 310.794.0558.



#### **INVENTORS**

► Yang, Xiangdong W.

#### OTHER INFORMATION

**KEYWORDS** 

research tool mouse model

therapeutics huntingtons disease

#### **CATEGORIZED AS**

▶ Research Tools

Animal Models

RELATED CASES

2005-492-0

# Gateway to Innovation, Research and Entrepreneurship

## **UCLA Technology Development Group**

10889 Wilshire Blvd., Suite 920,Los Angeles,CA 90095 tdg.ucla.edu

Tel: 310.794.0558 | Fax: 310.794.0638 | ncd@tdg.ucla.edu

© 2013 - 2014, The Regents of the University of California

Terms of use

Privacy Notice







